Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News on Pharma

Nearly 2,000 drug manufacturing plants are overdue for FDA inspections after COVID delays, AP finds

U.S. health inspectors are still struggling to address a massive backlog of pharmaceutical plants that went uninspected during disruptions caused by COVID-19

The Independent UK

Florida Transit Agency Introduces Narcan Kits To Combat Overdoses

Pinellas Suncoast Transit Authority in Florida takes proactive steps to address opioid crisis by training employees and installing Narcan kits at terminals.

Top News

Another Radeon RX 8000 GPU spotted in transit — Navi 44 XL GPU hints that RDNA 4 may mimic RDNA in product segmentation

The lifecycle of AMD's new (but still unannounced) GPU continues, and now we're seeing the low-end version move in shipping manifests.

Tom’s Hardware

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Oncology Stocks With Major Upside

With the rising prevalence of chronic diseases, increasing cell and gene therapies, and rising tech adoption in the biotech industry, the oncology market is booming. Amid this backdrop, investors could consider quality biotech stocks Pyxis Oncology (PYXS), Immatics (IMTX), and Jazz Pharmaceuticals (JAZZ), having significant upside potential. Continue reading.

StockNews.com

‘A faulty contraceptive coil left me crippled in pain and forced to have a hysterectomy’

Mother tells Maya Oppenheim she was forced into having a hysterectomy which meant she ‘car crashed into menopause’ at the age of 45

The Independent UK

AMD reportedly delays B840 and B850 motherboards to early 2025 — only X870 and X870E will launch in September

AMD's budget-friendly B850 and B840 chipset motherboards will seemingly arrive in 2025, limiting AMD's September launch to its higher-end X-series chipsets.

Tom’s Hardware

Biden-⁠Harris: Price Cuts on 10 Drugs to Save Medicare Beneficiaries $1.5 Billion

Historic Medicare drug price negotiations are said to lower costs on 10 best-selling drugs, saving Medicare beneficiaries $1.5 billion in out-of-pocket costs in the program's first year.

Kiplinger

Read news from The Economist, FT, and more,
with one subscription

Big Pharma Push Back On First Medicare Drug Price Cuts

Major pharmaceutical companies lashed out following a landmark deal unveiled Thursday to cut the costs of 10 key medicines, with some saying the price-setting process was not transparent.

International Business Times

Big Pharma fought to keep prices high

Big Pharma exploited patent laws to stifle competition amid Medicare price negotiations, according to a new report

Salon

Reeves should nail down UK AstraZeneca deal. A collapse would be embarrassing

Chancellor hopes to cut state aid for Speke vaccine plant to £40m. But pro-growth Treasury must not let project slip overseas

The Guardian - UK

Blow to AstraZeneca vaccine project as Reeves plans funding cuts

Chancellor reportedly seeking to cut £20m from the £65m promised by Hunt to Merseyside manufacturing plant

The Guardian - UK

BranchLab Adds Errol Taylor as Advisor with Additional States Making Pharma Marketing More Difficult

Startup says it can provide consumer privacy and campaign effectiveness

Broadcasting & Cable

FTSE 100 chief executive pay reaches highest level on record

Bosses of UK’s biggest companies are now paid 120 times more than average full-time worker in some instances

The Guardian - UK

‘Mind-boggling’: Victorian outreach workers decry double standard for lifesaving overdose drug naloxone

Untrained bystanders can legally administer the opioid-reversal treatment – but frontline staff workers face a legal risk if they do not first call triple zero

The Guardian - AU

Get all your
news in one place.

100's of premium titles.
One news app.

Kiplinger

Eli Lilly's Weight-Loss Drugs Fuel Beat-And-Raise Quarter

Eli Lilly stock is surging after the pharma giant beat Q2 estimates and lifted its full-year outlook. Here's what you need to know.

StockNews.com

3 Biotech Stocks With Anticipated Strong Earnings Reports

With highly effective drugs and treatment options, chronic disease prevalence, and adoption of technology, the biotech market is thriving. Hence, fundamentally solid biotech stocks Illumina (ILMN), Amgen (AMGN), and Entrada Therapeutics (TRDA) could be ideal with anticipated strong earnings reports. Read more.

The Independent UK

Drugstores tinker with new looks as their usual way of doing business faces challenges

America’s drugstores are testing smaller locations and more ways to offer care as more store closings loom

The Guardian - UK

GSK’s health is improving. Shame about the legal heartburn

Emma Walmsley’s overhaul seems to be delivering the goods even if US worries have left the share price becalmed

Get all your
news in one place.

100's of premium titles.
One news app.

Kiplinger

Pfizer Stock Slips After Beat-And-Raise Quarter: What to Know

Pfizer reported a notable year-over-year decline in Q2 earnings, but the results still beat expectations. Here's what investors should know.

The Guardian - UK

Reckitt Benckiser’s shares slump after Abbott baby formula ruling over bowel disease link

British group says claims products cause serious bowel condition NEC are ‘not supported by science’

AAP

'Grinding halt': shortage could cause hospital chaos

Australia's health system could come to a "grinding halt" within days if a shortage of intravenous fluid isn't addressed, a leading doctor has warned.

International Business Times

Bosses Resign At Japan Health Supplement Firm Probing Deaths

The chairman and president of a major Japanese dietary supplement maker announced their resignation on Tuesday, as the company probes dozens of deaths potentially linked to products meant to lower cholesterol.

The Conversation

Dear Pharmac – do things differently: what David Seymour’s expectations could mean for the drug-buying agency

Associate Health Minister David Seymour’s recent letter of expectations to drug buying agency Pharmac could fundamentally change the way the organisation makes decisions. Some of these changes could also make Pharmac’s job harder and its decisions more unpopular.

The Guardian - US

Ozempic knockoffs flood US market thanks to ‘blind spot’ in FDA rules

Pharmacy alliance president counters that ‘it’s an intentional policy’ so patients don’t go without medication

International Business Times

UN Urges Gilead To 'Make History' With Game-changing HIV Drug

Gilead could bring the AIDS pandemic towards an end if the US pharmaceutical giant opens up access to its game-changing new HIV drug, the head of UNAIDS told AFP. Winnie Byanyima urged Gilead to "make history" by allowing generic manufacturing of Lenacapavir, a twice-yearly injectable antiretroviral medication used to treat…

1 … 31 32 33 34

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.